Dapagliflozin in Patients With Critical Illness

Summary

To assess the effects of dapagliflozin on a composite hierarchical endpoint in critically ill patients.

Timeline

Start

2022-11-01

Primary completion

2023-10-20

Completion

2023-10-20

Publications

• Tavares CAM, Azevedo LCP, Guimaraes PO, Rea-Neto A, David-Joao PG, Campos NS, Amendola CP, Kozesinski-Nakatani AC, Filiponi TC, Almeida GMB, Bergo RR, Lobo SM, Tognon AP, Tavares MS, Silveira FS, Dracoulakis MDA, Biondi RS, Monfardini F, Nieri J, Madrini V Jr, Serpa-Neto A, Bacal F, Lemos PA, Berwanger O, Ezekowitz JA, Zampieri FG; DEFENDER Investigators. Dapagliflozin in Acute Cardiovascular Conditions: Insights From the DEFENDER Trial. JACC Adv. 2026 Jan;5(1):102459. doi: 10.1016/j.jacadv.2025.102459. Epub 2025 Dec 19.
• Tavares CAM, Azevedo LCP, Rea-Neto A, Campos NS, Amendola CP, Kozesinski-Nakatani AC, David-Joao PG, Lobo SM, Filiponi TC, Almeida GMB, Bergo RR, Guimaraes-Junior MRR, Figueiredo RC, Castro JR, Schuler CJ, Westphal GA, Carioca ACR, Monfradini F, Nieri J, Neves FMO, Paulo JA, Albuquerque CSN, Silva MCR, Kosiborod MN, Pereira AJ, Damiani LP, Correa TD, Serpa-Neto A, Berwanger O, Zampieri FG; DEFENDER Investigators. Dapagliflozin for Critically Ill Patients With Acute Organ Dysfunction: The DEFENDER Randomized Clinical Trial. JAMA. 2024 Aug 6;332(5):401-411. doi: 10.1001/jama.2024.10510.
• Tavares CAM, Azevedo LCP, Rea-Neto A, Campos NS, Amendola CP, Bergo RR, Kozesinski-Nakatani AC, David-Joao PG, Westphal GA, Guimaraes Junior MRR, Lobo SMA, Tavares MS, Dracoulakis MDA, Souza GM, Almeida GMB, Gebara OCE, Tomba PO, Albuquerque CSN, Silva MCR, Pereira AJ, Damiani LP, Correa TD, Serpa-Neto A, Berwanger O, Zampieri FG. Dapagliflozin in patients with critical illness: rationale and design of the DEFENDER study. Crit Care Sci. 2023 Dec 22;35(3):256-265. doi: 10.5935/2965-2774.20230129-en. eCollection 2023.

Drugs

Indications